Debio1143-Scchn-301- A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study Of Debio 1143 In Combination With Platinum-Based Chemotherapy And Standard Fractionation Intensity-Modulated Radiotherapy In Patients With Locally Advanced Squamous Cell Car
Posted Date: May 5, 2021
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The primary objective of the study is to demonstrate superior efficacy of Debio 1143 vs placebo when added to chemoradiotherapy (CRT) in locally advanced squamous cell carcinoma of the head and neck. Efficacy will be determined by measuring Event Free survival.
Criteria:
Histologically Confirmed Diagnosis In Previously Untreated Locally Advanced Squamous Cell Carcinoma Of The Head And Neck, Ecog 0-1, Peripheral Neuropathy < Grade 2, Adequate Hematologic, Renal And Hepatic Function, No Primary Tumor Of Nasopharyngeal, Paranasal Sinuses, Nasal Or Oral Cavity, Salivary, Thyroid Or Parathyroid Gland Pathologies, Skin Or Unknown Primary Site, No Metastatic Disease, No Prior Definitive Or Adjuvant Radiotherapy (Rt) And/Or Radical Surgery To The Head And Neck Region Which May Jeopardize The Primary Tumor Irradiation Plan,
Keywords:
Hnscc, Head And Neck Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com